EGFR and breast cancer: Mouse xenograft models of a subcutaneous EGFR-overexpressing BC xenograft (UMUC-5) showed a significant attenuation of tumour growth when treated with 120 μg of anti-EGFR-IR700 (panitumumab-IR700) and irradiated at 24 h (100 J/cm2) and 48 h (50 J/cm2) post-administration; with a third of tumours completely regressing.